Enhancing immunotoxin cell-killing activity via combination therapy with ABT-737.

Enhancing immunotoxin cell-killing activity via combination therapy with ABT-737.

Immunotoxins are antibody-toxin fusion proteins directed to kill cancer cells displaying specific target antigens on their surface. Remarkably, immunotoxins directed to CD22 on hairy cell leukemia have produced complete remissions in approximately 60% of patients enrolled in phase I/II trials. For r...

Full description

Bibliographic Details
Main Authors:	Fitzgerald, D, Moskatel, E, Ben-Josef, G, Traini, R, Tendler, T, Sharma, A, Antignani, A, Mussai, F, Wayne, A, Kreitman, R, Pastan, I
Format:	Journal article
Language:	English
Published:	2011

Similar Items

ABT-737 synergizes with Bortezomib to kill melanoma cells
by: Steven N. Reuland, et al.
Published: (2012-02-01)

Synergistic anticancer effects of the 9.2.27PE immunotoxin and ABT-737 in melanoma.
by: Karianne Risberg, et al.
Published: (2011-01-01)

Immunotoxins: From Design to Clinical Application
by: Robert J. Kreitman, et al.
Published: (2021-11-01)

Development of Recombinant Immunotoxins for Hairy Cell Leukemia
by: Robert J. Kreitman, et al.
Published: (2020-08-01)

The BH3-mimetic ABT-737 effectively kills acute myeloid leukemia initiating cells
by: Denis V. Baev, et al.
Published: (2014-01-01)

Immunotoxins: The Role of the Toxin
by: David FitzGerald, et al.
Published: (2013-08-01)

The combination of BH3-mimetic ABT-737 with the alkylating agent temozolomide induces strong synergistic killing of melanoma cells independent of p53.
by: Steven N Reuland, et al.
Published: (2011-01-01)

Exploiting the synergy between carboplatin and ABT-737 in the treatment of ovarian carcinomas
by: Jain, H, et al.
Published: (2012)

An Anti-PSMA Immunotoxin Reduces Mcl-1 and Bcl2A1 and Specifically Induces in Combination with the BAD-Like BH3 Mimetic ABT-737 Apoptosis in Prostate Cancer Cells
by: Anie P. Masilamani, et al.
Published: (2020-06-01)

Exploiting the synergy between carboplatin and ABT-737 in the treatment of ovarian carcinomas.
by: Harsh Vardhan Jain, et al.
Published: (2014-01-01)

Synergistic antitumor effects of 9.2.27-PE38KDEL and ABT-737 in primary and metastatic brain tumors.
by: Xin Yu, et al.
Published: (2019-01-01)

Cytotoxicity of the anti-CD22 immunotoxin HA22 (CAT-8015) against paediatric acute lymphoblastic leukaemia.
by: Mussai, F, et al.
Published: (2010)

Effect of antigen shedding on targeted delivery of immunotoxins in solid tumors from a mathematical model.
by: Youngshang Pak, et al.
Published: (2014-01-01)

Combination treatments with the PKC inhibitor, enzastaurin, enhance the cytotoxicity of the anti-mesothelin immunotoxin, SS1P.
by: Abid R Mattoo, et al.
Published: (2013-01-01)

Melatonin Can Modulate the Effect of Navitoclax (ABT-737) in HL-60 Cells
by: Alexey Lomovsky, et al.
Published: (2020-11-01)

Interactions Between Pseudomonas Immunotoxins and the Plasma Membrane: Implications for CAT-8015 Immunotoxin Therapy
by: Monika Bokori-Brown, et al.
Published: (2018-11-01)

Rational Formulation of targeted ABT-737 nanoparticles by self-assembled polypeptides and designed peptides
by: Polina Aibinder, et al.
Published: (2024-02-01)

The BH3 mimetic ABT-737 increases treatment efficiency of paclitaxel against hepatoblastoma
by: Fuchs Jörg, et al.
Published: (2011-08-01)

Proteasomal degradation of Mcl-1 by maritoclax induces apoptosis and enhances the efficacy of ABT-737 in melanoma cells.
by: Manoj K Pandey, et al.
Published: (2013-01-01)

The inhibition of Beclin1-dependent autophagy sensitizes PTC cells to ABT737-induced death
by: Ning Hu, et al.
Published: (2024-03-01)

Curcumin at Low Doses Potentiates and at High Doses Inhibits ABT-737-Induced Platelet Apoptosis
by: Natalia Rukoyatkina, et al.
Published: (2021-05-01)

Cooperation of IRAK1/4 inhibitor and ABT-737 in nanoparticles for synergistic therapy of T cell acute lymphoblastic leukemia
by: Wu X, et al.
Published: (2017-10-01)

Rapid detection of an ABT-737-sensitive primed for death state in cells using microplate-based respirometry.
by: Pascaline Clerc, et al.
Published: (2012-01-01)

ABT-737 Synergizes with Cisplatin Bypassing Aberration of Apoptotic Pathway in Non-small Cell Lung Cancer
by: Eun Young Kim, et al.
Published: (2017-04-01)

Upregulating Noxa by ER stress, celastrol exerts synergistic anti-cancer activity in combination with ABT-737 in human hepatocellular carcinoma cells.
by: Hong Zhu, et al.
Published: (2012-01-01)

Cooperation of IRAK1/4 inhibitor and ABT-737 in nanoparticles for synergistic therapy of T cell acute lymphoblastic leukemia [Corrigendum]
by: Wu X, et al.
Published: (2018-01-01)

Immunotoxin complementation of HAART to deplete persisting HIV-infected cell reservoirs.
by: Edward A Berger, et al.
Published: (2010-06-01)

BCL2L10 Is Overexpressed in Melanoma Downstream of STAT3 and Promotes Cisplatin and ABT-737 Resistance
by: María Josefina Quezada, et al.
Published: (2020-12-01)

ABT-737 reverses the acquired radioresistance of breast cancer cells by targeting Bcl-2 and Bcl-xL
by: Li Ji-Yu, et al.
Published: (2012-12-01)

RNA silencing of Mcl-1 enhances ABT-737-mediated apoptosis in melanoma: role for a caspase-8-dependent pathway.
by: Angela M Keuling, et al.
Published: (2009-01-01)

Immunogenicity of Immunotoxins Containing Pseudomonas Exotoxin A: Causes, Consequences, and Mitigation
by: Ronit Mazor, et al.
Published: (2020-06-01)

Comparison of putative BH3 mimetics AT-101, HA14-1, sabutoclax and TW-37 with ABT-737 in platelets
by: Hao Wei, et al.
Published: (2021-01-01)

The BCL‐2 family protein inhibitor ABT‐737 as an additional tool for the treatment of EBV‐associated post‐transplant lymphoproliferative disorders
by: Aude Robert, et al.
Published: (2020-10-01)

Mechanisms of Resistance to Immunotoxins Containing <i>Pseudomonas</i> Exotoxin A in Cancer Therapy
by: Michael Dieffenbach, et al.
Published: (2020-06-01)

The Application of Arsenic Trioxide in Ameliorating ABT-737 Target Therapy on Uterine Cervical Cancer Cells through Unique Pathways in Cell Death
by: I-Lun Hsin, et al.
Published: (2019-12-01)

Use of human cancer cell lines mitochondria to explore the mechanisms of BH3 peptides and ABT-737-induced mitochondrial membrane permeabilization.
by: Nelly Buron, et al.
Published: (2010-03-01)

Sorafenib Sensitizes Glioma Cells to the BH3 Mimetic ABT-737 by Targeting MCL1 in a STAT3-Dependent Manner
by: Irina Kiprianova, et al.
Published: (2015-07-01)

BMX Acts Downstream of PI3K to Promote Colorectal Cancer Cell Survival and Pathway Inhibition Sensitizes to the BH3 Mimetic ABT-737
by: Danielle S. Potter, et al.
Published: (2014-02-01)

Pseudomonas Exotoxin Immunotoxins and Anti-Tumor Immunity: From Observations at the Patient’s Bedside to Evaluation in Preclinical Models
by: Yasmin Leshem, et al.
Published: (2019-01-01)

A single-chain immunotoxin against carcinoembryonic antigen that suppresses growth of colorectal carcinoma cells.
by: Akamatsu, Y, et al.
Published: (1998)